Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6667804 | 0.82 | MRGPRX4 (0.51) | MRGPRX4ENPP2PRSS1PRSS2PRSS3 | |
| SCHEMBL24606488 | 0.82 | SLC5A2 (0.36) | TSHRSMN1; SMN2NPC1TP53 | |
| SCHEMBL510248 | 0.81 | LTA4H (0.36) | PRSS1PRSS2PRSS3TSHRSMN1; SMN2 | |
| SCHEMBL20250618 | 0.80 | ACHE (0.35) | — | |
| SCHEMBL22763249 | 0.79 | IDO1 (0.55) | — | |
| SCHEMBL17121369 | 0.78 | POLB (0.33) | TSHRNPC1HSD17B10 | |
| SCHEMBL470893 | 0.77 | TSHR (0.61) | TSHRSMN1; SMN2NPC1 | |
| SCHEMBL17757999 | 0.76 | IDO1 (0.57) | — | |
| SCHEMBL20547932 | 0.76 | MRGPRX4 (0.46) | MRGPRX4ENPP2PRSS1PRSS2PRSS3 | |
| SCHEMBL29928701 | 0.76 | MRGPRX4 (0.46) | MRGPRX4ENPP2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | MRGPRX4 756/4885ENPP2 161/4885PRSS1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.